Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acrivon Therapeutics, Inc. (ACRV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Acrivon is a clinical stage biopharmaceutical company focused on precision oncology medicines developed using its Generative Phosphoproteomics AP3 platform, and its filings offer additional context on financial results, clinical programs, and business updates.
Among the documents available for ACRV are current reports on Form 8-K, which Acrivon uses to furnish press releases announcing quarterly financial results and to provide Regulation FD disclosures. For example, the company has filed 8-K reports to attach earnings press releases summarizing research and development expenses, cash and investment balances, and narrative business highlights, as well as to furnish a corporate presentation describing AP3 capabilities, synergy data for ACR-368 and ACR-2316 with immune checkpoint inhibitors, and updates to its pipeline overview.
Through this page, users can track how Acrivon reports its progress with lead programs such as ACR-368, a CHK1/CHK2 inhibitor in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, and ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, along with AP3-driven preclinical initiatives. Real-time updates from EDGAR ensure that new ACRV filings, including additional 8-Ks and other periodic reports, are reflected as they become available.
Stock Titan’s interface is designed to pair these filings with AI-powered summaries that explain the key points of each document in clear language. Users can quickly see what each ACRV filing covers—such as financial condition, clinical data highlights, or platform developments—while retaining the ability to open the full SEC text for detailed review, including any exhibits like press releases or corporate presentations incorporated by reference.
Acrivon Therapeutics insiders reported tax-related share dispositions tied to restricted stock unit vesting. The filing shows 1,302 shares of Common Stock disposed at $1.63 per share, leaving 2,094,469 shares owned following this transaction.
A separate indirect transaction reports a tax-withholding disposition of 579 Common Stock shares at $1.63 per share, with 314,127 shares owned indirectly afterward. Footnotes explain shares were withheld by the issuer to satisfy mandatory tax withholding and that certain holdings are through a spouse, with each spouse disclaiming beneficial ownership beyond their pecuniary interest.
Acrivon Therapeutics, Inc. insider Mary Miller, the company’s Chief Legal Officer, reported a routine share withholding related to equity compensation. On 01/17/2026, 659 shares of common stock were withheld at a price of $1.98 per share to cover mandatory tax withholding when her restricted stock units vested. After this transaction, she beneficially owned 33,896 shares of Acrivon common stock, held directly. This type of transaction does not represent an open-market sale but an automatic tax-related adjustment.
Acrivon Therapeutics’ President and CEO, Dr. Peter Blume-Jensen, reported buying 49,000 shares of common stock on January 14, 2026, in an open-market purchase at a weighted average price of $1.676 per share. The trades were executed in multiple lots at prices ranging from $1.66 to $1.68 per share. Following this transaction, he directly holds 2,095,771 common shares.
The filing also reports 314,706 common shares held indirectly through co-founder and EVP Dr. Kristina Masson. Footnotes state that Dr. Masson disclaims beneficial ownership of Dr. Blume-Jensen’s directly held shares, and Dr. Blume-Jensen likewise disclaims beneficial ownership of Dr. Masson’s shares, except to the extent of each spouse’s pecuniary interest.
Acrivon Therapeutics, Inc. Chief Financial Officer Adam D. Levy reported an open-market purchase of the company’s common stock. On January 14, 2026, he bought 8,832 shares of Acrivon common stock in a series of trades at a weighted average price of $1.6983 per share, with individual trade prices ranging from $1.695 to $1.7086. Following this transaction, he beneficially owned 20,983 shares of Acrivon common stock, held in direct ownership.
Acrivon Therapeutics, Inc. Chief Operating Officer Eric Devroe reported an open-market purchase of company stock. On 01/13/2026, he bought 10,000 shares of Acrivon common stock at a weighted average price of $1.7218 per share, executed in multiple trades within a price range of $1.719 to $1.7268. Following this purchase, he beneficially owns 75,308 shares of Acrivon common stock in direct ownership.
Acrivon Therapeutics, Inc. reported that it hosted a corporate webcast and conference call on January 8, 2026, featuring a presentation by its leadership team and an interactive Q&A session. In connection with this event, the company posted a presentation on its investor relations website titled the January 8, 2026 Data Update. This presentation includes clinical data and program updates for the ACR-368 program as well as initial clinical data for ACR-2316.
The same January 8, 2026 Data Update has been furnished as Exhibit 99.1 to this report under a Regulation FD disclosure item, and is expressly not deemed filed for liability purposes under the Exchange Act unless later specifically incorporated by reference.
Acrivon Therapeutics reported preliminary unaudited cash, cash equivalents and investments of about $119 million as of December 31, 2025, which it currently expects will fund operations into the second quarter of 2027. This extends its financial runway as it advances multiple oncology programs.
The company highlighted updated Phase 2b data for ACR-368 in endometrial cancer, with an overall response rate of 39% in one trial arm and higher confirmed response rates in serous endometrial cancer, guiding a focus on this subgroup and expansion of Arm 3 into the EU with up to 90 subjects. Initial Phase 1 results for ACR-2316 showed tolerability and tumor shrinkage, including a confirmed partial response in endometrial cancer and unconfirmed responses in small cell and squamous non-small cell lung cancers.
Acrivon also nominated ACR-6840, a CDK11 inhibitor, as its next development candidate and outlined milestones through 2026, including Phase 2 updates and Phase 3 readiness for ACR-368, further ACR-2316 data and dose expansion, an IND submission for ACR-6840, and additional AP3-driven programs.
Acrivon Therapeutics, Inc. insiders report routine share withholding for taxes. President and CEO Dr. Peter Blume-Jensen reported that on 11/21/2025, 19,904 shares of common stock were disposed of at $2.30 per share, identified as shares withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units. Following this transaction, he beneficially owned 2,046,771 shares directly and 314,706 shares indirectly.
The indirect holdings reflect spousal ownership between co-founders Dr. Blume-Jensen and EVP – Business Operations Dr. Kristina Masson. Each spouse disclaims beneficial ownership of the other's securities except to the extent of their pecuniary interest, which clarifies how their combined economic exposure to Acrivon’s stock is reported.
Acrivon Therapeutics, Inc. (ACRV) reported an administrative insider transaction by its Chief Accounting Officer. On 11/14/2025, 99 shares of common stock were withheld by the company at a price of $2.24 per share to cover mandatory tax withholding upon the vesting of restricted stock units. After this tax-related share withholding, the officer beneficially owned 4,122 shares of Acrivon common stock directly.
Acrivon Therapeutics, Inc. reported an insider equity transaction involving its Chief Legal Officer. On 11/14/2025, 184 shares of common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being sold in an open-market transaction.
After this tax withholding event, the reporting officer beneficially owns 34,555 shares of Acrivon Therapeutics common stock, held directly. The Form 4 is filed by a single reporting person and reflects routine equity compensation administration for the officer role.